课题基金 / 基金详情

GENE THERAPY FOR RHEUMATOID ARTHRITIS AIMING TELOMERASE AS A TARGET

GENE THERAPY FOR RHEUMATOID ARTHRITIS AIMING TELOMERASE AS A TARGET
以端粒酶为靶标的类风湿关节炎基因疗法
批准号:
10670412
负责人:
MAEDA Hiroyuki
金额:
$2.05万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
1998
资助国家:
日本
项目状态:
已结题
起止时间:
1998 至 1999

项目摘要

项目成果

MAEDA Hiroyuki的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Telomerase is essential for the indefinite proliferation of human cells. And its activation plays a circle role in cellular immortality. We have shown that detection of telomerase activity in synovial tissues is useful for diagnosis of rheumatoid arthritis (RA). We also have shown that telomerase activity in RA synovial tissue is likely derived from infiltrating mononuclear cells and may be involved in the pathogenesis of RA and that the presence of tetomerase activity in RA may be an indicator of an aggressive phenotype.We evaluated peptide nucleic acids, (PNAS) - mediated inhibition of telomerase activity in various cell lines. The antisense PNAS against a part of telomerase gene demonstrated little inhibitory effect on telomerase activity, indicating that cellular uptake might be a limiting factor.Next, an adenovirus vector expressing antisense mRNA against a part of telomerase gene was constructed. Telomerase activities in various human cell lines infected with ,the vector were not inhibited. The result indicate that the construct of the vector needs to be further investigated.Further, an adenovirus vector expressing lipocortin 1, an endogenous anti-inflammation mediator, was constructed. A549 cells infected with the vector showed reduced prostaglandin E2 production, which indicate the vector could mimic a part of actions of corticosteroid. Further exploration for new therapeutic strategy should be continued.
期刊论文(101)
专著(0)
科研奖励(0)
会议论文
Hiyama E.et al.: "Application of telomerase ingibitors for gastrointestinal cancer therapy" J.Clin.Exp.Med.(Japanese). 184(12). 907-911 (1998)
Hiyama E.等人:“端粒酶抑制剂在胃肠道癌症治疗中的应用”J.Clin.Exp.Med.(日文)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Murakami I.: "p53 Gene mutations are asscciated with shortened survival in patients with asvanced non-small cell lung cancer:an analysis of medicall managed patients"Clin Cancer Res. 6. 526-530 (2000)
Murakami I.:“p53 基因突变与晚期非小细胞肺癌患者的生存期缩短相关:对医疗管理患者的分析”Clin Cancer Res。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Ishioka S.: "Thicpurine methyltransferase genotype and the toxicity of azathioprine in Japanese"Intern Med. 38. 944-947 (1999)
Ishioka S.:“日本的噻嘌呤甲基转移酶基因型和硫唑嘌呤的毒性”Intern Med。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Ishioka S.: "Two asymptomatic dases with sarcoidosis demonstrated sequential evolution from radiographic stage I to II within five years"Hiroshima J Med Sci. 48. 101-3 (1999)
Ishioka S.:“两个无症状结节病患者在五年内表现出从放射照相 I 期到 II 期的连续演变”Hiroshima J Med Sci。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
93
    The prediction of the endocrine therapy response for metastatic breast cancer using FES-PET.
    • 批准号:
      22591426
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $1.83万
    • 财政年份:
      2010
    • 负责人:
      MAEDA Hiroyuki
    • 依托单位:
    Systemic Optimality Theoretic Studies on Japanese Phonological History
    • 批准号:
      20520411
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $1.25万
    • 财政年份:
      2008
    • 负责人:
      MAEDA Hiroyuki
    • 依托单位:
    Construction and Study of Parallel Dialectal Speech Corpus for the Contrastive Analysis of SFP(Sentence Final Particle)'s Intonation
    • 批准号:
      15520253
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $1.22万
    • 财政年份:
      2003
    • 负责人:
      MAEDA Hiroyuki
    • 依托单位:
    Relationship between Cenozoic volcanic-hydrothermal activities and epithermal Au-Ag-Cu-Pb-Zn mineralizations in the Shiretoko Peninsula, Hokkaido, Japan (2006)
    • 批准号:
      15540455
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $1.66万
    • 财政年份:
      2003
    • 负责人:
      MAEDA Hiroyuki
    • 依托单位:
    海外基金